# Incannex Healthcare (IXHL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IXHL
## Company Profile
- Ticker: IXHL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Australia and listed in the U
## Stock Data
- Close: 3.25 USD
- Market cap: 36491889.699999996 USD
- Last updated: 2026-09-03
## Business Overview
Incannex Healthcare is a biotechnology company focused on cannabinoid-based and related therapies for inflammatory and sleep disorders. Its story is centered on translating cannabinoid science into specialty treatments.
## Why The Stock Is Moving

As of Sep 3, 2026, IXHL closed down 0.61% at $3.25. No new same-company headline was identified in the current news window.

## Geographic Base

Incannex is headquartered in Australia and listed in the U.S. market. It sits in specialty biotechnology with a cannabinoid and inflammation focus.

## Business Model

The company depends on clinical data, regulatory progress, and capital efficiency while it develops a narrow pipeline. Investors watch early signals and commercialization potential.

## Landscape Position

Incannex occupies a niche cannabinoid-biotech position. The stock is catalyst-sensitive because the company still needs to prove its therapeutic thesis in the clinic.

## Future Catalysts

- Incannex’s catalysts are its cannabinoid / inflammatory-disease programs and any clinical step that keeps the platform alive. The stock remains highly event-driven.

## Recent News
- 2026-08-25 12:46 EST — [Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X](https://biopharmsignal.com/news/IXHL/incannex-announces-first-patient-dosed-in-dreamzz-phase-2-study-of-ihl-42x-d0e7cc09) — Source: Incannex Healthcare
- 2026-08-11 12:00 EST — [Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026](https://biopharmsignal.com/news/IXHL/incannex-receives-additional-a-5-1-million-r-d-tax-incentive-refund-completing-m-3efef88d) — Source: Incannex Healthcare
- 2026-07-23 12:00 EST — [Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea](https://biopharmsignal.com/news/IXHL/incannex-commences-participant-screening-in-dreamzz-phase-2-study-of-ihl-42x-for-752babf4) — Source: Incannex Healthcare
- 2026-06-25 12:00 EST — [Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea](https://biopharmsignal.com/news/IXHL/incannex-secures-u-s-patent-grant-for-ihl-42x-in-obstructive-sleep-apnea-e23ab89e) — Source: Incannex Healthcare
- 2026-06-10 12:00 EST — [Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility](https://biopharmsignal.com/news/IXHL/incannex-receives-a-6-0-million-r-d-tax-incentive-refund-for-fy25-further-streng-c634fd54) — Source: Incannex Healthcare